Related Experiment Video

Updated: Apr 28, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

7.1K

Targeting the androgen receptor with steroid conjugates

Paul M Levine1, Michael J Garabedian, Kent Kirshenbaum

  • 1Department of Chemistry, New York University , New York, New York 10003, United States.

Journal of Medicinal Chemistry
|June 18, 2014
PubMed

Insights

Targeting the androgen receptor (AR) is crucial for prostate cancer treatment. This review explores steroid and nonsteroidal conjugates designed for potent and selective AR engagement, offering future therapeutic prospects.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • The androgen receptor (AR) is a key therapeutic target in prostate cancer.
  • Elevated AR expression in tumors correlates with prostate cancer progression.
  • Targeted therapies offer potential to reduce systemic toxicities compared to traditional chemotherapies.

Purpose of the Study:

  • To review strategies for developing potent steroid conjugates targeting the androgen receptor.
  • To evaluate nonsteroidal conjugates and their potential in AR pharmacology.
  • To discuss future directions for AR-targeted therapies in prostate cancer.

Main Methods:

  • Literature review of existing and emerging strategies for AR-targeting agents.
  • Analysis of steroid and nonsteroidal conjugate designs for selective AR engagement.
  • Evaluation of potential applications in androgen receptor pharmacology.

Main Results:

  • Various strategies exist to create potent steroid conjugates for selective AR targeting.
  • Nonsteroidal conjugates also show promise for AR engagement.
  • These approaches offer potential for targeted prostate cancer treatment.

Conclusions:

  • Developing selective AR-targeting agents, particularly conjugates, is a promising therapeutic strategy.
  • Future research should focus on optimizing these conjugates for clinical application in prostate cancer.
  • Targeting the androgen receptor remains a central focus in prostate cancer drug development.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.6K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

7.4K

Related Concept Videos

Intracellular Hormone Receptors01:08

Intracellular Hormone Receptors

Lipid-soluble hormones diffuse across the plasma and nuclear membrane of target cells to bind to their specific intracellular receptors. These receptors act as transcription factors that regulate gene expression and protein synthesis in the target cell
45.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.5K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids01:19

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
1.3K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.1K